| Fecha | Trimestre | Sesión | BPA (est → real) | Ingresos (est → reales) |
|---|---|---|---|---|
| 4 nov 2026Próximo | Q3 2026 | — | 1,62 | 850 M |
29 ago 2026
Insulet Corporation delivered strong Q2 2026 results with 23.5% revenue growth, strong customer additions, and solid profitability. Click for more on PODD.
27 ago 2026
Insulet Corp (PODD) fits the affordable growth screen: strong EPS and revenue growth, reasonable valuation, and overall solid profitability.
26 ago 2026
Opportunities include AI-enabled adherence platforms, connected inhalers, injectors and smart packaging, telehealth and home-care integration, chronic disease support, and pharmacy-led services in underserved and Asia-Pacific markets. Medication Adherence Market Medication Adherence Market Dublin, Aug. 26, 2026 (GLOBE NEWSWIRE) -- The "Medication Adherence Market by Type of Solution, Type of Product, Route of Administration, Therapeutic Area, End-user, and Key Geographical Regions- Trends and Fo
ACTON, Mass., August 26, 2026--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the Wells Fargo 21st Annual Healthcare Conference in Boston on Wednesday, September 9, 2026, at 2:15 p.m. (Eastern Time).
25 ago 2026
Insulet has considerably underperformed the broader market over the past year, but analysts are cautiously optimistic about the stock’s prospects.
Insulet's Q2 beat and stronger margins contrast with a 2026 growth reset, putting U.S. Type 2 retention at the center of its outlook.
24 ago 2026
McEvoy invested $162,217 at a weighted average price of $147.47, bringing total beneficial ownership to 23,735 shares valued at $3.52 million.
Disclosed in the latest SEC filing, a significant insider purchase on August 24, involves Ashley McEvoy, President and CEO at Insulet (NASDAQ:PODD). What Happened: McEvoy made a significant move by purchasing 1,100
14 ago 2026
Insulet’s second quarter was marked by strong revenue expansion but a sharp negative market reaction, as investors focused on emerging challenges in the company’s type 2 diabetes segment. While broad-based demand for Omnipod drove growth across both U.S. and international markets, CEO Ashley McEvoy acknowledged that lower-than-expected retention rates among new type 2 users weighed on results. McEvoy stated, “We should have identified the issue sooner,” signaling a more cautious approach to comm
13 ago 2026
Alpha Wealth Funds, LLC, an investment management company, released its Q2 2026 letter for the “Insiders Fund”. A copy of the letter is available to download here. The Fund lost 1.45% in June, while it was up 8.43% for the 2nd quarter and 0.75% YTD. This compares to the S&P 500’s -0.95%, 15.2%, and 9.98% […]
12 ago 2026
Type 2 retention challenges force management to trim full-year outlook despite revenue beat.
10 ago 2026
Insulet's Q2 results beat estimates on strong Omnipod demand and wider margins, but its 2026 revenue outlook takes a hit.
7 ago 2026
Insulet stock has fallen sharply over the past year, yet both its Discounted Cash Flow (DCF) intrinsic value estimate and market multiples currently point to the shares trading below what the underlying business may be worth. Over the past 12 months, Insulet has declined 54.1%, which means the market has already priced in a lot of pessimism. The recent cut to full year revenue growth expectations after an earnings beat can weigh on sentiment, while any renewed confidence in Insulet's long...
6 ago 2026
Canaccord Genuity analyst William Plovanic maintains Insulet (NASDAQ:PODD) with a Buy and lowers the price target from $249 to $179.
Insulet's (PODD) execution challenges in serving Type 2 diabetes patients, upcoming competition in p
Leerink Partners analyst Mike Kratky downgrades Insulet (NASDAQ:PODD) from Outperform to Market Perform and lowers the price target from $247 to $145.
TD Cowen analyst Mathew Blackman maintains Insulet (NASDAQ:PODD) with a Hold and lowers the price target from $294 to $144.
UBS analyst Patrick Wood maintains Insulet (NASDAQ:PODD) with a Neutral and lowers the price target from $174 to $150.
RBC Capital analyst Shagun Singh maintains Insulet (NASDAQ:PODD) with a Outperform and lowers the price target from $245 to $160.
Investing.com -- JPMorgan downgraded insulin pump maker Insulet to Neutral from Overweight, citing slowing U.S. sales growth, rising attrition among Type 2 diabetes patients and a weaker-than-expected outlook for 2027, while slashing its price target to $152 from $275.
